Table 2 Cardiometabolic parameters in response to n-3 PUFA or placebo supplementation, in baseline and after 8 weeks (follow up)
n-3 PUFA (n = 15) | Placebo (n = 15) | ||||||
|---|---|---|---|---|---|---|---|
Baseline | Follow-up | Diff. Mean (95% CI) | Baseline | Follow-up | Diff. Mean (95% CI) | P value* | |
HbA1c (%) | 6.11 ± 0.57 | 6.47 ± 0.86 | 7.01 ± 1.06 | 7.40 ± 1.72 | |||
Log HbA1c (%)b | 0.17 ± 0.01 | 0.16 ± 0.02 | −0.008 (− 0.014 to − 0.002) | 0.14 ± 0.02 | 0.14 ± 0.02 | − 0.005 (− 0.020 to 0.010) | 0.752 |
Glucose (mg/dl) | 134.7 ± 10.1 | 131.1 ± 6.7 | − 3.5 (− 0.01 to 4.7) | 130.8 ± 5.5 | 122.8 ± 4.6 | −8.0 (− 2.5 to 9.2) | 0.382 |
Triglycerides (mg/dl) | 136.5 ± 75.9 | 113.3 ± 71.4 | 152.9 ± 59.5 | 153 ± 56.4 | |||
Log Triglycerides (mg/dl)b | 0.009 ± 0.004 | 0.011 ± 0.005 | 0.002 (0.000 to 0.004)** | 0.008 ± 0.003 | 0.008 ± 0.003 | 0.000 (− 0.001 to 0.001) | 0.005 |
Total Cholesterol (mg/dl) | 182.4 ± 41.3 | 177.1 ± 44.7 | − 5.8 (− 17.8 to 6.1) | 192.3 ± 38.2 | 193.3 ± 40.4 | 0.7 (− 15.8 to 17.2) | 0.385 |
HDL-cholesterol (mg/dl) | 49.7 ± 15.9 | 52 ± 15 | 2.3 (− 0.5 to 5.1) | 51.7 ± 12.2 | 53.9 ± 12.7 | 2.1 (− 3.0 to 7.2) | 0.904 |
LDL-cholesterol (mg/dl) | 105.4 ± 35.3 | 102.4 ± 41.4 | − 3.9 (− 16.4 to 8.6) | 110.0 ± 35.6 | 108.8 ± 41.7 | −1.4 (− 16.9 to 14.1) | 0.732 |
Albuminuria (mg/dl) | 9.67 ± 6.06 | 8.89 ± 7.04 | 5.64 ± 3.52 | 3.99 ± 2.25 | |||
Log Albuminuria (mg/dl)a | 2.25 ± 0.59 | 1.92 ± 0.49 | − 0.33 (− 0.73 to 0.07) | 2.91 ± 0.82 | 2.74 ± 1.04 | − 0.16 (− 0.93 to 0.60) | 0.426 |